Glucarpidase: Difference between revisions
(Creation of page) |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[antidote]] | |||
*Dosage Forms: 1000 units/vial | *Dosage Forms: 1000 units/vial | ||
*Routes of Administration: IV | *Routes of Administration: IV | ||
| Line 55: | Line 56: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Latest revision as of 20:14, 22 September 2019
Administration
- Type: antidote
- Dosage Forms: 1000 units/vial
- Routes of Administration: IV
- Common Trade Names: Voraxaze
Adult Dosing
- Methotrexate toxicity
- 50 units/kg IV x1
- For patients with mod-severe renal impairment
- 50 units/kg IV x1
Pediatric Dosing
- Methotrexate toxicity
- 50 units/kg IV x1
- For patients with mod-severe renal impairment
- 50 units/kg IV x1
Special Populations
- Pregnancy Rating: C; Benefits outweigh risks during pregnancy
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: No adjustment
- Pediatric: Not defined
Hepatic Dosing
- Adult: No adjustment
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 5.6 hr, 8.2 hr (Crcl < 30)
- Metabolism: Unknown
- Excretion: Unknown
Mechanism of Action
- Hydrolyzes carboxyl-terminal glutamate, converting methotrexate to inactive metabolisms.